Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists

Affiliations

¹ Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Center for Lymphoma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
³ Ontario Institute for Cancer Research, Toronto, Canada.
⁴ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts5Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Oreofe O Odejide et al. JAMA Intern Med. 2016 Feb.

. 2016 Feb;176(2):263-5.

doi: 10.1001/jamainternmed.2015.6599.

¹ Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Center for Lymphoma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
³ Ontario Institute for Cancer Research, Toronto, Canada.
⁴ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts5Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

No abstract available

Comment in

Addressing End-of-Life Quality Gaps in Hematologic Cancers: The Importance of Early Concurrent Palliative Care.
LeBlanc TW. LeBlanc TW. JAMA Intern Med. 2016 Feb;176(2):265-6. doi: 10.1001/jamainternmed.2015.6994. JAMA Intern Med. 2016. PMID: 26720324 No abstract available.